Your session is about to expire
← Back to Search
Incentive-Based Intervention for Substance Abuse Disorders
Phase 2
Recruiting
Led By Mindy Waite, PhD
Research Sponsored by Aurora Health Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment
Age at least 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial will test whether offering people with substance abuse disorders incentive payments for healthy behaviors helps them combat their addiction.
Who is the study for?
This trial is for adults over 18 who have used opioids, cocaine, or methamphetamine non-medically in the last 21 days. Participants must be currently receiving some form of substance abuse treatment and meet specific medical criteria for substance use disorders. They need to have a smartphone with a data plan, an email they can access on their phone, and be willing to download and use the DynamiCare app.
What is being tested?
The study tests two incentive-based approaches using an app called DynamiCare to promote abstinence from drug use among individuals with opioid or cocaine addiction. One approach increases rewards over time (escalating), while the other decreases them (de-escalating) as participants demonstrate continued abstinence.
What are the potential side effects?
Since this trial involves behavioral interventions through an app rather than medications, there are no direct physical side effects like those associated with drugs. However, participants may experience psychological effects related to changes in behavior due to the incentives.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am currently in a substance abuse treatment program.
Select...
I am 18 years old or older.
Select...
I have a smartphone with a data plan and can download the DynamiCare app.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Abstinence from Opioid and/or Cocaine Use
Secondary study objectives
Negative Saliva Analysis Frequency
Negative Urinalysis Frequency
Psychotherapy Completion
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
7Treatment groups
Experimental Treatment
Active Control
Group I: Escalating LowExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and "reset" to the lowest amount when a test is positive or missed. The "Low" group will receive incentives worth $2-$8.
Group II: Escalating HighExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and "reset" to the lowest amount when a test is positive or missed. The "High" group will receive incentives worth $4-$16.
Group III: De-Escalating LowExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The "Low" group will receive incentives worth $6-12.
Group IV: De-Escalating HighExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The "High" group will receive incentives worth $10-$20.
Group V: Constant LowExperimental Treatment1 Intervention
In the Constant groups, incentive amounts will remain unchanged across time. The "Low" group will receive incentives worth $8 every test.
Group VI: Constant HighExperimental Treatment1 Intervention
In the Constant groups, incentive amounts will remain unchanged across time. The "High" group will receive incentives worth $16.
Group VII: ControlActive Control1 Intervention
Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.
Find a Location
Who is running the clinical trial?
Aurora Health CareLead Sponsor
45 Previous Clinical Trials
15,818 Total Patients Enrolled
University of ChicagoOTHER
1,056 Previous Clinical Trials
760,309 Total Patients Enrolled
University of California, Santa CruzOTHER
4 Previous Clinical Trials
1,521 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am currently in a substance abuse treatment program.I am currently in a substance abuse treatment program.You may benefit from contingency management if you meet at least one of the following criteria:I am 18 years old or older.I started substance use treatment within the last 2 weeks.I have a smartphone with a data plan and can download the DynamiCare app.I do not have severe cognitive issues that require a legal guardian.I have a smartphone with a data plan and am willing to download the DynamiCare app.You have used illegal drugs such as opioids, cocaine, and methamphetamine within the past 3 weeks.I started substance use treatment within the last 2 weeks.I am at least 18 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Constant Low
- Group 2: De-Escalating High
- Group 3: Escalating High
- Group 4: De-Escalating Low
- Group 5: Control
- Group 6: Escalating Low
- Group 7: Constant High
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Opioid Use Disorder Patient Testimony for trial: Trial Name: NCT04927143 — Phase 2
Share this study with friends
Copy Link
Messenger